Xenon Pharmaceuticals (XENE) Profit After Tax (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Profit After Tax data on file, last reported at -$102.3 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 57.27% year-over-year to -$102.3 million in Q1 2026; TTM through Mar 2026 was -$385.3 million, a 52.36% decrease from a year earlier, with the FY2025 full-year figure at -$345.9 million, down 47.62% from the prior year.
• Profit After Tax for Q1 2026 stood at -$102.3 million, up from -$107.4 million in the prior quarter.
• Over the last five years, Profit After Tax for XENE reached as high as -$19.7 million in Q1 2022 and fell as low as -$107.4 million in Q4 2025.
• Historically, Profit After Tax has averaged -$58.6 million across 5 years, with a median of -$48.1 million in 2023.
• Across the five-year window, Profit After Tax tumbled 153.25% in 2022 and fell 14.87% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$37.4 million in 2022, then retreated by 19.78% to -$44.8 million in 2023, then sank by 49.81% to -$67.1 million in 2024, then tumbled by 59.99% to -$107.4 million in 2025, then increased by 4.7% to -$102.3 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$102.3 million in Q1 2026, -$107.4 million in Q4 2025, and -$90.9 million in Q3 2025.